DOCSLIB.ORG

Pharmacy Data Management Drug Exception List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacy Data Management Drug Exception List Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML INJ 1.00 ML 37 CODEINE PO4 60MG/ML INJ 1.00 ML 38 CODEINE PO4 15MG/ML INJ 1.00 ML NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 39 CODEINE PO4 15MG/5ML SOLN,ORAL 1.00 ML 40 CODEINE PO4 5MG/ML SYRUP 1.00 ML 41 CODEINE PO4 30MG/ML (PF) INJ 1.00 ML 42 CODEINE PO4 60MG/ML (PF) INJ 1.00 ML 43 CODEINE PO4 30MG/ML INJ,CARPUJECT,2ML 2 ML 44 CODEINE PO4 30MG/ML (PF) INJ,TUBEX,1ML 1.00 ML 45 CODEINE PO4 60MG/ML (PF) INJ,TUBEX,1ML 1.00 ML 47 COLCHICINE 0.5MG/ML INJ 1.00 ML 52 QUINIDINE GLUCONATE 80MG/ML INJ 1.00 ML 60 QUINIDINE SO4 200MG/ML INJ 1.00 ML 96 PHENOBARBITAL 20MG/5ML ELIXIR 1.00 ML 97 PHENOBARBITAL NA 120MG/VIL INJ 5.00 ML 98 PHENOBARBITAL NA 130MG/ML INJ 1.00 ML 99 PHENOBARBITAL NA 65MG/ML INJ 1.00 ML 100 PHENOBARBITAL NA 32MG/ML INJ 1.00 ML 102 PHENOBARBITAL 15MG/5ML ELIXIR 1.00 ML 106 PHENOBARBITAL 18.5MG/5ML ELIXIR 1.00 ML 108 PHENOBARBITAL NA 60MG/ML INJ 1.00 ML 111 PHENOBARBITAL 20MG/5ML ELIXIR,15ML 15.00 ML 113 ERGONOVINE MALEATE 0.2MG/ML INJ 1.00 ML 116 DIETHYLSTILBESTROL DIPHOSPHATE 50MG/ML INJ 1.00 ML 127 PAPAVERINE HCL 30MG/ML INJ 1.00 ML 137 METHADONE HCL 10MG/ML INJ 1.00 ML 139 METHADONE HCL 10MG/ML SOLN,ORAL 1.00 ML 140 METHADONE HCL 1MG/ML SOLN,ORAL 1.00 ML 141 METHADONE HCL 10MG/5ML SOLN,ORAL 1.00 ML 146 METHADONE HCL 5MG/20ML SOLN,ORAL 1.00 ML 147 METHADONE HCL 10MG/20ML SOLN,ORAL 1.00 ML 148 METHADONE HCL 15MG/20ML SOLN,ORAL 1.00 ML 149 METHADONE HCL 20MG/20ML SOLN,ORAL 1.00 ML 150 METHADONE HCL 25MG/20ML SOLN,ORAL 1.00 ML 151 METHADONE HCL 30MG/20ML SOLN,ORAL 1.00 ML 152 METHADONE HCL 35MG/20ML SOLN,ORAL 1.00 ML 153 METHADONE HCL 40MG/20ML SOLN,ORAL 1.00 ML 154 METHADONE HCL 45MG/20ML SOLN,ORAL 1.00 ML 155 METHADONE HCL 50MG/20ML SOLN,ORAL 1.00 ML 156 METHADONE HCL 55MG/20ML SOLN,ORAL 1.00 ML 157 METHADONE HCL 60MG/20ML SOLN,ORAL 1.00 ML NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 158 METHADONE HCL 65MG/20ML SOLN,ORAL 1.00 ML 159 METHADONE HCL 70MG/20ML SOLN,ORAL 1.00 ML 160 METHADONE HCL 75MG/20ML SOLN,ORAL 1.00 ML 161 METHADONE HCL 80MG/20ML SOLN,ORAL 1.00 ML 162 METHADONE HCL 85MG/20ML SOLN,ORAL 1.00 ML 163 METHADONE HCL 90MG/20ML SOLN,ORAL 1.00 ML 164 METHADONE HCL 95MG/20ML SOLN,ORAL 1.00 ML 165 METHADONE HCL 100MG/20ML SOLN,ORAL 1.00 ML 166 METHADONE HCL 0.58MG/ML SOLN,ORAL 1.00 ML 175 METHYLTESTOSTERONE PWDR 1.00 GM 179 PENICILLIN G K 200000UNT/VIL INJ 1.00 ML 180 PENICILLIN G K 1MILLION UNT/VIL INJ 1.00 ML 181 PENICILLIN G K 5MILLION UNT/VIL INJ 1.00 ML 182 PENICILLIN V K 125MG/5ML SOLN,ORAL 1.00 ML 183 PENICILLIN V K 250MG/5ML SOLN,ORAL 1.00 ML 184 PENICILLIN G K 20MILLION UNT/VIL INJ 1.00 ML 185 PENICILLIN G PROCAINE 300000UNT/ML INJ,SUSP 1.00 ML 189 PENICILLIN G PROCAINE 600000UNT/1.2ML INJ,SUSP 1.00 ML 191 PENICILLIN G NA 5MILLION UNT/VIL INJ 1.00 ML 193 PENICILLIN G K 10MILLION UNT/VIL INJ 1.00 ML 194 PENICILLIN G K 400000UNT/5ML SOLN,ORAL 1.00 ML 195 PENICILLIN G PROCAINE 600000UNT/ML INJ,SUSP 1.00 ML 196 PENICILLIN G BENZATHINE 600000UNT/ML INJ,SUSP 1.00 ML 197 PEN G BENZATHINE 300000UNT/PEN G PROCAINE 300000UNT/ML INJ,SUSP 1.00 ML 199 PEN G BENZATHINE 450000UNT/PEN G PROCAINE 150000UNT/ML INJ,SUSP 1.00 ML 200 PENICILLIN G BENZATHINE 300000UNT/ML INJ,SUSP 1.00 ML 201 PEN G BENZATHINE 150000UNT/PEN G PROCAINE 150000UNT/ML INJ,SUSP 1.00 ML 202 PENICILLIN G PROCAINE 1500000UNT/VIL INJ 1.00 ML 203 PENICILLIN G K 250000UNT TAB 1.00 ML 205 PENICILLIN G K 250000UNT/5ML SOLN,ORAL 1.00 ML 209 PENICILLIN G K 100000UNT/5ML SOLN,ORAL 1.00 ML 211 PENICILLIN G BENZATHINE 1.2MILLION UNT/VIL INJ 1.00 ML 212 PENICILLIN G PROCAINE 3MILLION UNT/VIL INJ,SUSP 1.00 ML 213 CYANOCOBALAMIN 1000MCG/ML INJ 1.00 ML 214 CYANOCOBALAMIN 100MCG/ML INJ 1.00 ML 215 CYANOCOBALAMIN 2MCG/ML INJ 1.00 ML 216 CYANOCOBALAMIN 20MCG/ML INJ 1.00 ML 217 CYANOCOBALAMIN 10MCG/ML INJ 1.00 ML NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 218 CYANOCOBALAMIN 30MCG/ML INJ 1.00 ML 226 CYANOCOBALAMIN 500MCG/0.1ML ACTUAT GEL,NASAL,5ML 5.00 ML 227 CYANOCOBALAMIN 40MCG/THIAMINE HCL 5MG/ML INJ 1.00 ML 228 CYANOCOBALAMIN 20MCG/THIAMINE HCL 5MG/ML INJ 1.00 ML 229 CYANOCOBALAMIN 1000MCG/THIAMINE HCL 100MG INJ 1.00 ML 230 CYANOCOBALAMIN 12.5MCG/THIAMINE 5.5MG/5ML LIQUID 1.00 ML 231 POTASSIUM CHLORIDE 2MEQ/ML INJ 1.00 ML 232 POTASSIUM CHLORIDE 20MEQ/15ML LIQUID 1.00 ML 233 POTASSIUM CHLORIDE 40MEQ/15ML LIQUID 1.00 ML 239 POTASSIUM CHLORIDE 15MEQ/PKT PWDR 1.00 GM 240 POTASSIUM CHLORIDE 2.4MEQ/ML INJ 1.00 ML 241 POTASSIUM CHLORIDE 3.2MEQ/ML INJ,CONC 1.00 ML 242 POTASSIUM CHLORIDE 1.5MEQ/ML INJ 1.00 ML 244 POTASSIUM CHLORIDE 25MEQ/PKT PWDR 1.00 GM 249 POTASSIUM CHLORIDE 30MEQ/15ML LIQUID 1.00 ML 250 POTASSIUM CHLORIDE 20MEQ/ML INJ 1.00 ML 251 POTASSIUM CHLORIDE 15MEQ/15ML LIQUID 1.00 ML 253 POTASSIUM CHLORIDE 0.67MEQ/ML INJ 1.00 GM 258 POTASSIUM CHLORIDE 3MEQ/ML INJ 1.00 ML 259 POTASSIUM CHLORIDE 20MEQ/15ML (SF) LIQUID 1.00 ML 260 POTASSIUM CHLORIDE 40MEQ/15ML (SF) LIQUID 1.00 ML 264 POTASSIUM CHLORIDE 20MEQ/15ML ELIXIR 1.00 ML 265 POTASSIUM CHLORIDE 25MEQ TAB 1.00 GM 266 POTASSIUM CHLORIDE 25MEQ TAB,EFFERVSC 1.00 GM 267 POTASSIUM CHLORIDE 20MEQ/5ML ELIXIR 1.00 ML 268 POTASSIUM CHLORIDE 20MEQ/15ML SOLN 1.00 ML 271 POTASSIUM CHLORIDE 10MEQ/50ML INJ,BAG 50.00 ML 272 POTASSIUM CHLORIDE 10MEQ/100ML INJ,BAG 100.00 ML 273 POTASSIUM CHLORIDE 20MEQ/100ML INJ,BAG 100.00 ML 274 POTASSIUM CHLORIDE 40MEQ/100ML INJ,BAG 100.00 ML 275 POTASSIUM CHLORIDE 20MEQ/50ML INJ,BAG 50.00 ML 276 POTASSIUM CHLORIDE 30MEQ/100ML INJ,BAG 100.00 ML 277 METOCURINE IODIDE 2MG/ML INJ 1.00 ML 278 LIVER EXTRACT 20MCG/ML INJ 1.00 ML 279 LIVER EXTRACT 2MCG/ML INJ 1.00 ML 280 SECOBARBITAL NA 50MG/ML INJ 1.00 ML 284 SECOBARBITAL NA PWDR 1.00 GM 285 PROGESTERONE 50MG/ML (IN OIL) INJ,SOLN 1.00 ML NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 286 PROGESTERONE 50MG/ML INJ 1.00 ML 287 PROGESTERONE 50MG/ML INJ,SOLN,SA 1.00 ML 288 PROGESTERONE 50MG/ML INJ,SUSP 1.00 ML 289 PROGESTERONE 25MG/ML INJ (IN OIL) 1.00 ML 290 PROGESTERONE 50MG/ML INJ,REPOSITORY 1.00 ML 291 PROGESTERONE 50MG/ML INJ (IN OIL) 1.00 ML 292 PROGESTERONE 38MG INSERT,CONT REL 1.00 ML 293 PROGESTERONE 50MG/ML INJ,SOLN 1.00 ML 294 PROGESTERONE PWDR 1.00 GM 295 PROGESTERONE 8% (90MG) GEL,VAG,APPLICATOR 1.45 GM 305 VANCOMYCIN HCL 5MG/ML INJ,BAG,100ML 100 ML 310 GLUCAGON 10MG/VIL INJ 1.00 ML 313 PROTAMINE SO4 10MG/ML INJ 1.00 ML 314 PROTAMINE SO4 10MG/ML (PF) INJ 1.00 ML 315 CAPREOMYCIN SO4 1GM/VIL INJ 1.00 ML 320 CEFAZOLIN NA 500MG/BAG INJ 1.00 ML 321 CEFAZOLIN NA 5GM/VIL INJ 1.00 ML 322 CEFAZOLIN NA 20GM/VIL INJ 1.00 ML 323 CEFAZOLIN NA 1GM/BAG INJ 1.00 ML 325 EMETINE HCL 65MG/ML INJ 1.00 ML 326 EPHEDRINE SO4 50MG/ML INJ 1.00 ML 327 EPHEDRINE SO4 25MG/ML INJ 1.00 ML 331 EPHEDRINE SO4 5MG/ML INJ 1.00 ML 332 EPHEDRINE SO4 20MG/5ML SYRUP 1.00 ML 333 SILVER NITRATE 1% SOLN,OPH 1.00 ML 335 SILVER NITRATE 10% SOLN,TOP 1.00 ML 336 SILVER NITRATE 25% SOLN,TOP 1.00 ML 337 SILVER NITRATE 50% SOLN,TOP 1.00 ML 338 SILVER NITRATE 10% OINT 1.00 GM 339 SILVER NITRATE CRYSTALS 1.00 GM 341 SILVER NITRATE 0.5% SOLN,TOP 1.00 ML 343 MAGNESIUM SO4 4MEQ/ML INJ 1.00 ML 344 MAGNESIUM SO4 1MEQ/ML INJ 1.00 ML 345 MAGNESIUM SO4 2MEQ/ML INJ 1.00 ML 346 MAGNESIUM SO4 0.8MEQ/ML INJ 1.00 ML 347 MAGNESIUM SO4 4MEQ/ML (PF) INJ 1.00 ML 348 MAGNESIUM SULFATE GRANULES 1.00 GM 349 MAGNESIUM SULFATE 40MEQ/5GM PWDR 1.00 GM NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 350 HISTAMINE PO4 2.75MG/ML INJ 1.00 ML 351 HISTAMINE PO4 2.75MG/5ML INJ 1.00 ML 352 HISTAMINE PO4 0.275MG/ML INJ 1.00 ML 353 HISTAMINE POSITIVE SKIN TEST CONTROL 1.00 ML 354 MORPHINE SO4 15MG/ML INJ 1.00 ML 358 MORPHINE SO4 2MG/ML INJ 1.00 ML 359 MORPHINE SO4 4MG/ML INJ 1.00 ML 360 MORPHINE SO4 8MG/ML INJ 1.00 ML 361 MORPHINE SO4 10MG/ML INJ 1.00 ML 365 MORPHINE SO4 20MG/ML SOLN,CONC,ORAL 1.00 ML 366 MORPHINE SO4 10MG/5ML SOLN,ORAL 1.00 ML 367 MORPHINE SO4 20MG/5ML SOLN,ORAL 1.00 ML 368 MORPHINE SO4 1MG/ML INJ 1.00 ML 369 MORPHINE SO4 5MG/ML INJ 1.00 ML 370 MORPHINE SO4 0.5MG/ML (PF) INJ 1.00 ML 371 MORPHINE SO4 1MG/ML (PF) INJ 1.00 ML 375 MORPHINE SO4 25MG/ML INJ 1.00 ML 380
Load more

Recommended publications
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Xifaxan® (Rifaximin)
    Wednesday, October 14, 2015 4 p.m. Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review Board Members FROM: Bethany Holderread, Pharm.D. SUBJECT: Packet Contents for Board Meeting – October 14, 2015 DATE: October 1, 2015 NOTE: The DUR Board will meet at 4:00 p.m. The meeting will be held at 4345 N Lincoln Blvd. Enclosed are the following items related to the October meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Action Item – Vote on 2016 Meeting Dates – Appendix B Update on Medication Coverage Authorization Unit/Bowel Preparation Medication Post-Educational Mailing – Appendix C Action Item – Vote to Prior Authorize Tykerb® (Lapatinib), Halaven® (Eribulin), Ixempra® (Ixabepilone), Kadcyla® (Ado-Trastuzumab), Afinitor® (Everolimus), & Perjeta® (Pertuzumab) – Appendix D Action Item – Vote to Prior Authorize Orkambi™ (Lumacaftor/Ivacaftor) – Appendix E Action Item – Vote to Prior Authorize Savaysa® (Edoxaban) – Appendix F Action Item – Vote to Prior Authorize Epanova® (Omega-3-Carboxylic Acids), Praluent® (Alirocumab), & Repatha™ (Evolocumab) – Appendix G Annual Review of Constipation and Diarrhea Medications and 30-Day Notice to Prior Authorize Movantik™ (Naloxegol), Viberzi™ (Eluxadoline), & Xifaxan® (Rifaximin) – Appendix H 30-Day Notice to Prior Authorize Daraprim® (Pyrimethamine) – Appendix I Annual Review of Allergy Immunotherapies and 30-Day Notice to Prior Authorize Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, & Kentucky Blue Grass Mixed Pollens Allergen Extract) – Appendix J Annual Review of Non-Steroidal Anti-Inflammatory Drugs and 30-Day Notice to Prior Authorize Dyloject™ (Diclofenac Sodium) – Appendix K ORI-4403 • P.O.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • 2021 SELECT EX FORMULARY the Following Is a List of the Most Commonly Prescribed Brand and Generic Medications
    2021 SELECT EX FORMULARY The following is a list of the most commonly prescribed brand and generic medications. It represents an abbreviated version of the formulary list that is at the core of your prescription drug benefit plan. The list is not all-inclusive and does not guarantee coverage. Some preferred medications overlap with other clinical programs and may not be covered. In addition to drugs on this list, the majority of generic medications are covered under your plan and you are encouraged to ask your doctor to prescribe generic drugs whenever appropriate. Search complete formulary drug information at elixirsolutions.com. PLEASE NOTE: Preferred brand drugs may move to non-preferred status if a generic version becomes available during the year. Any medication approved to enter the market will not be covered until reviewed by Elixir. Not all drugs listed are covered by all prescription drug benefit programs. For specific questions about your coverage, please visit elixirsolutions.com. A B CILOXAN OINTMENT digoxin abacavir tablet balsalazide CIMDUO diltiazem ER (except generics for abacavir-lamivudine BAQSIMI cinacalcet CARDIZEM LA) ABILIFY MAINTENA [INJ] BASAGLAR [INJ] ciprofloxacin dimethyl fumarate DR* abiraterone* BD ULTRAFINE INSULIN SYRINGES ciprofloxacin-dexamethasone diphenoxylate-atropine acetic acid & NEEDLES citalopram dipyridamole ER-aspirin acitretin BELBUCA CITRANATAL divalproex sodium ACUVAIL BELSOMRA clarithromycin divalproex sodium ER acyclovir capsule, tablet benzonatate (except NDCs: clarithromycin ER DIVIGEL
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Doxapram Shortens Recovery Following Sevoflurane Anesthesia [Le Doxapram Hâte La Récupération Après Une Anesthésie Au Sévoflurane]
    456 CANADIAN JOURNALGENERAL OF ANESTHESIA ANESTHESIA Doxapram shortens recovery following sevoflurane anesthesia [Le doxapram hâte la récupération après une anesthésie au sévoflurane] Chi-Chen Wu MD,* Martin S. Mok MD,* Jui-Yuan Chen MD,† Gong-Jhe Wu MD,† Yeong-Ray Wen MD,† Chao-Shun Lin MD* Purpose: A randomized, double blind controlled trial was possibilité de serrer la main sur demande, le temps d’extubation et undertaken to investigate the effect of doxapram on recovery le score de récupération d’Aldrete. Les valeurs de l’index bispectral, times and bispectral index following sevoflurane anesthesia. la tension artérielle systolique et la fréquence cardiaque ont été Methods: Upon completion of surgery under sevoflurane anes- enregistrées avant l’anesthésie, pendant l’opération et à chaque thesia, 60 adult patients were randomly allocated to receive minute pendant 15 min après l’administration du médicament. either doxapram hydrochloride 1 mg·kg–1 iv or saline placebo. Résultats : Le temps écoulé avant l’ouverture des yeux a été plus Clinical recovery from anesthesia was assessed by time to eye court avec le doxapram qu’avec le placebo (6,9 ± 2,2 min vs 9,9 opening on verbal command, hand squeezing on command, ± 3,1 min, P < 0,05). Les scores moyens de l’index bispectral ont time to extubation, and the Aldrete recovery score. Bispectral été aussi plus élevés avec le doxapram sept à huit minutes après index values, systolic blood pressure, and heart rate were l’administration du médicament expérimental (P < 0,05). Un recorded at baseline (before anesthesia), during surgery, and retour à la conscience plus rapide a été associé à une plus grande every minute for 15 min after administration of the study drug.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • 4-Aminobenzoic Acid (PABA)
    SCCP/1008/06 EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Public Health and Risk Assessment C7 - Risk assessment SCIENTIFIC COMMITTEE ON CONSUMER PRODUCTS SCCP Opinion on 4-Aminobenzoic acid (PABA) COLIPA n° S1 Adopted by the SCCP during the 8th plenary meeting of 20 June 2006 SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ TABLE OF CONTENTS 1. BACKGROUND ………………………………………………… 3 2. TERMS OF REFERENCE ……………………………………………….... 3 3. OPINION ………………………………………………… 4 4. CONCLUSION ………………………………………………… 48 5. MINORITY OPINION ………………………………………………… 48 6. REFERENCES ………………………………………………… 48 7. ACKNOWLEDGEMENTS ………………………………………………… 56 2 SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 1. BACKGROUND PABA or 4-Aminobenzoic acid (PABA) is listed in Annex VII part 1 no. 1 on the List of permitted UV filters that may be used in cosmetic products. The maximum authorised concentration in finished cosmetic products is 5 %. No other limitations and requirements or conditions of use and warnings are required by the SCCP. In 2001, the Commission received inquiries from Denmark expressing its concern about the use of certain UV filters in cosmetic products. In this connection an opinion on PABA was missing, as the substance has been introduced into the Annexes of the cosmetics legislation based on safety evaluations from the Member States prior to the existence of the SCCNFP. Submission I on the UV-filter 4-Aminobenzoic acid (PABA) was submitted December 2005. 2. TERMS OF REFERENCE 1. Is 4-Aminobenzoic acid (PABA) safe for continued use as a UV filter in cosmetic products under the current restriction of 5.0 % as a maximum concentration? 2. Does the SCCP consider that the use of 4-Aminobenzoic acid (PABA) is safe for the consumer in a concentration up to 5 % when used in other cosmetic products than sunscreen products? 3.
    [Show full text]